4 articles
Indian shares opened little changed after the Federal Reserve held rates steady, amidst geopolitical risks pushing Brent crude lower. Meanwhile, Sun Pharma gained approval to manufacture semaglutide i
Sun Pharma received South African regulatory approval to manufacture and sell a generic version of semaglutide, challenging Novo Nordisk and Eli Lilly in the diabetes and obesity drug market.
Jefferies reported Q2 profit doubling driven by M&A advisory fees, including advising on Sun Pharma's $11.75B acquisition of Organon and Kelonia's sale to Eli Lilly.
India's Sun Pharmaceutical Industries agreed to acquire U.S. drugmaker Organon & Co in an all-cash deal valued at approximately $11.75 billion. The transaction grants Sun Pharma full ownership of the
ChemBrief